辣木提取物降脂作用的研究

目的探讨辣木提取物预防性降脂的作用。方法选用SD雄性大鼠为研究对象,通过喂养高脂膳食建立预防性肥胖高血脂模型,用辣木提取物进行辅助降脂试验,依据保健食品功能学评价规程进行。大鼠随机分为正常对照组、高脂模型对照组、辣木提取物高剂量组、中剂量组、低剂量组,实验后检测各组大鼠体重、血液生化指标(总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白)、脂肪重量和脂/体比、Lee′s指数。结果大鼠灌胃辣木提取物40 d后,各实验组血脂水平明显低于高脂模型对照组,其中高剂量组的血清总胆固醇、甘油三脂与高脂模型对照组相比分别有显著性差异(P<0.05)和极显著性差异(P<0.01)。辣木提取物各剂量组大鼠的肾周脂肪重量和附睾脂肪重量、脂/体比、Lee′s指数极显著低于高脂模型对照组(P<0.01)。结论辣木提取物具有良好的辅助降血脂作用。

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer

OBJECTIVE To evaluate the efficacy and adverse effects ofgemcitabine versus pegylated liposomal doxorubicin in patientswith progressive or recurrent ovarian cancer.METHODS We conducted a systematic literature search toidentify all randomized controlled trials comparing gemcitabineand pegylated liposomal doxorubicin for progressive orrecurrent ovarian cancer. Trial data were reviewed and extractedindependently by 2 reviewers. We evaluated the quality of theincluded studies using the Handbook 5.0 recommend standardsand then analyzed data by Cochrane Collaboration's RevMan 5.0.RESULTS Two trials which included a total of 348 patients wereanalyzed. The results of meta-analysis showed that gemcitabineimproved disease control rates significantly better than pegylatedliposomal doxorubicin. A greater number of patients receivinggemcitabine experienced neutropenia compared with patientsreceiving pegylated liposomal doxorubicin; however, hand-footsyndrome and mucositis were more severe in patients receivingpegylated liposomal doxorubicin.CONCLUSION Gemcitabine provided a limited advantagecompared with pegylated liposomal doxorubicin. There existsan urgent need for more high-quality, multicenter, adequaterandomized, controlled clinical trials for comparing gemcitabinewith pegylated liposomal doxorubicin in patients withprogressive/recurrent ovarian cancer.

Resolution of pleural effusion in a IgD multiple myeloma after chemotherapy based on liposomal doxorubicin

IgD myelomas account for only 2% of all myelomas. This kind of hematological malignancy is severe and carries a bleak prognosis. Pleural effusion is very rare in multiple myeloma. We reported a case in which pleural effusion appeared at the end of the illness of IgD myeloma and treated with liposomal doxorubicin.

The Influence of Forage/Concentrate Ratio and Full Fat Soya By-Pass Supplementation on the Fatty Acids Profile from the Carcase of Fatting Lambs

There was organized a 2×2 factorial type experience in which it has been aimed the influence of forage/concentrates ratio and the effect of supplementing the ratio with full fat soya by-pass （FFS） on the production performance and carcass fatty acid profile of fattening lambs. 32 Tsigai lambs were divided into 4 groups and were fed with 2 different diets regarding the forage/concentrates ratio （35/65 and 65/35, on a DM basis）, containing or not 5% FFS （full fat soya treated with formaldehyde 12.5%）. Including FFS in diet and the ratios rich in concentrates determined a significant improvement in weight gain （P〈0.01）, in the degree of food recovery and in fatty acid profile from the carcass. It has been significantly increased （P〈0.01） the weight of polyunsaturated fatty acids （PUFA） from intramuscular fat （longissimus dorsi-LD and femoral biceps-FB） and the deposit fat （subcutaneous-SC and perirenal-PR） and decreased the proportion of saturated （SFA） and monounsaturated fatty acids （MUFA）. Most significant differences were recorded about PUFA from Omega-3 series （C18：3 n-3, EPA C22：3 n-3, DPA and DHA） and CLA isomers （conjugated linolenic acid： C 18：2 C9, tl I＋C 18：2 t10, C 12）. The best profile of fatty acids, considered in light of the influence on human health （high concentration of Omega 3 fatty acids and CLA and low in SFA） was established in LD, for lambs fed with diets high in concentrates and which contained FFS （HC/S）.

Effects of electroacupuncture combined with auricular plaster on F% and waist-hip ratio in simple obesity patients

Objective To observe and compare the difference of clinical therapeutic effect of electroacupuncture combined with auricular plaster therapy and electroacupuncture therapy on simple obesity. Methods sixty female patients of simple obesity were randomly divided into two groups： an electroacupuncture group and a combined group. Each group had 30 patients treated respectively with electroacupuncture and electroacupuncture therapy combined with auricular point pressing therapy. The changes of the body mass index （BMI）, body fat percentage （F%）, and waist-hip ratio （WHR） were observed to evaluate the effect of loosing weight. Results Compared with the scores before treatment, the BMI, F%, WHR level in two groups dropped （ all P〈0.01 ） in all 60 patients. And compared with the electroacupuncture group, the combined group dropped more obviously （ P〈0.05, P〈0.01 ） . Conclusion The effects of electroacupuncture therapy and electroacupuncture combined with auricular plaster therapy on simple obesity were both remarkable, but more in the combined group, so it indicates that the combined therapy is better than single therapy.

Antitumor efficacy of doxorubicin encapsulated in neovasculature targeting liposomes

It was reported that a 5-amino acid peptide Ala-Pro-Arg-Pro-Gly （APRPG） could specifically bind to the tumor angiogenic site. We investigated the antitumor efficacy of doxorubicin （DOX） encapsulated in APRPG modified liposome （APRPG-LP） compared with DOX encapsulated in non-APRPG modified liposomes （LP） and DOX solution （flee DOX） on Lewis lung carcinoma （LLC） bearing mice. APRPG-LP could efficiently suppress the tumor growth of the experimental mice, compared with LP （P〈0.001）, free DOX （P〈0.001） and saline of negative control （P〈0.001）. The present results demonstrated that the APRPG modified liposomes exhibited a much better therapeutic efficacy over the non-modified liposomes and the DOX solution, because of the effect of targeted tumor angiogenesis disruption. Thus, APRPG-LP could be a promising active-targeting drug carrier to tumor angiogenic site.

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Breast cancer is one of the malignant tumors with the highest morbidity and mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by treating breast cancer with adjuvant chemotherapy, so as to increase the cure rate or survival of patients. In recent years, liposomes have been regarded as a kind of new carrier for targeted drugs. Being effective for enhancing drug efficacy and reducing side effects, they have been widely used for devel- oping anticancer drugs. As a kind of anthracycline with high anticancer activity, doxorubicin can treat or alleviate a variety of malignant tumors effectively when it is used on its own or in combination with other anticancer drugs~ Alt- hough liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of breast cancer, its exact therapeutic efficacy and side effects have not been definitely proven. Various clinical studies have adopted different combined regimes, dosages, and staging, so their findings differ to certain extent. This paper reviews the clinical application of liposomal doxorubicin in the adjuvant chemotherapy of breast cancer and illustrates therapeutic effects and side effects of pegylated liposomal doxorubicin （PLD） and non-PLD （NPLD） in clinical research, in order to discuss the strategies for applying these drugs in such adjuvant chemotherapy, looking forward to providing references for related research and clinical treatment in terms of dosage, staging, combined regimes, and analysis methods and so on.